For decades, pharmaceutical R&D has labored under Eroom's Law, the observation that the inflation-adjusted cost of developing a new drug roughly doubles every nine years, despite relentless scientific and technological progress. AI promises to bend that curve. But there's a structural constraint the industry can't wish away: scientific data are not engineered for machines. They're fragmented across instrument silos, locked in formats optimized for human interpretation, and stripped of the context that makes them useful for computation at scale.
The NVIDIA BioNeMo Agent Toolkit (read announcement here), with its purpose-built foundation models and agentic infrastructure for life sciences, represents a serious effort to change what's possible in drug discovery, protein design, genomics, and lab automation. Its combination with TetraScience and the Tetra OS is what makes those capabilities work in the real world.
The constraint isn't models — it's the quality of your fuel
Data is the fuel AI needs to drive discoveries. Most biopharma organizations are starved for AI-native scientific data: governed, structured, and engineered for reuse. Massive hidden costs sit in the 60–80% of scientist effort spent wrangling heterogeneous instrument outputs, reconciling metadata, and rebuilding brittle pipelines — work that doesn't compound and fails under real-world variance across labs, sites, and vendors. Without a governed data substrate, even the best foundation models underperform because the inputs lack consistency, context, and lineage.
"An agent built on fragmented, ungoverned scientific data will make fragmented, ungoverned decisions — faster."
This is where Tetra OS operates. Its Scientific Data Foundry deconstructs raw scientific outputs such as imaging, LC-MS chromatograms, scRNA-seq matrices, bioreactor time-series, and ELN context into high-quality fuel for AI-native data schemas, taxonomies, and ontologies designed for machine consumption and cross-domain integration. Models receive inputs that are standardized, documented, and trustworthy. That's not a minor operational detail. It's the difference between a foundation model that performs in a demo and one that holds up across programs, sites, and regulatory environments.
"Scientific AI cannot be built on fragmented data. Our work with NVIDIA is grounded in that reality,” says TetraScience co-founder and CEO Patrick Grady. “ When instrument data is transformed into AI-native form through the Scientific Data Foundry, models like those in the NVIDIA BioNeMo Agent Toolkit have something worth reasoning on. That's the combination that turns agentic workflows from a demonstration into a durable capability across biopharma R&D."
Putting it to work: Lead Clone Selection
Cell line development is one of the most consequential bottlenecks between drug discovery and manufacturing. Identifying stable, high-producing clones typically takes around eight months: hundreds of candidates screened, phenotypic signals integrated with genotypic markers, advancement decisions made under uncertainty.
We've built a working demonstration of what changes when models from the BioNeMo Agent Toolkit run on properly industrialized scientific data. The Tetra Lead Clone Selection Assistant integrates microscopy, bioreactor, LC-MS, flow cytometry, and scRNA-seq outputs through the Scientific Data Foundry, then applies NVIDIA’s VISTA-2D for cell morphology analysis and a proprietary ML model for gene expression signals tied to clone stability and productivity. Factory-built scoring components combine those features into multi-modal clone rankings. Tetra AI surfaces recommendations and flags uncertainty, so scientists stay in control while the system handles the data complexity underneath.
The result: cell line development timelines compressed from eight months to 2.5 months, with substantially higher confidence in which clones will hold up at manufacturing scale.
Why this matters for agentic science
The BioNeMo Agent Toolkit enables AI agents to reason, plan, and execute across biological workflows. That's a meaningful advance. But agents are only as reliable as the data environment they operate in. An agent built on fragmented, ungoverned scientific data will make fragmented, ungoverned decisions — faster.
TetraScience's role in this ecosystem is to make the data layer worthy of the model layer. Once scientific data are industrialized in the Foundry and workflows are productized in the Scientific Use Case Factory, the same substrate can power adjacent use cases — high-throughput screening analytics, chromatography insights, CMC deviation detection — without rebuilding the plumbing each time. That's what compounding looks like in practice: each use case makes the next one faster and more reliable.
The path from AI pilot to production-grade scientific intelligence requires both sides of this equation. NVIDIA brings the open models and software, the compute, and increasingly the agentic infrastructure. TetraScience brings the data foundation that lets those capabilities operate at enterprise scale, with the governance and lineage that regulated industries actually require.